Safety and exploratory efficacy of bosutinib in amyotrophic lateral sclerosis: a phase 2 trial using external controls
Abstract Background Bosutinib, a selective Src/c-Abl inhibitor approved for the treatment of chronic myelogenous leukemia (CML), was identified as a molecularly targeted therapeutic candidate for amyotrophic lateral sclerosis (ALS) through induced pluripotent stem cell-based drug repurposing. To evaluate its safety and tolerability and explore its efficacy in ALS, an exploratory, multicenter, open-label phase 2 clinical trial was conducted. Methods This study included a 12-week observation period and a 24-week treatment period enrolling patients diagnosed with ALS within 2 years of symptom onset. Eligible patients were centrally allocated (1:1) to receive oral bosutinib at either 200 mg/day or 300 mg/day for 24 weeks. In lieu of a placebo control arm, efficacy was assessed using two external control datasets: placebo data of the edaravone Study MCI186-19 and registry data from the multicenter ALS cohort study, JaCALS, with outcomes evaluated by the total ALS Functional Rating Scale-Revised (ALSFRS-R). Results Between April 2022 and January 2024, 33 participants were screened, and 26 received bosutinib. Of these, 22 completed the 24-week treatment period and 4 discontinued treatment, primarily because of adverse events, with hepatic toxicity being the most common reason for discontinuation. No new safety signals specific to patients with ALS were identified. As a primary endpoint, the mean change from baseline in ALSFRS-R score at week 24 showed a smaller reduction in both dose groups compared with the placebo group in MCI186-19. The exploratory JaCALS comparison suggested a potential clinical signal of bosutinib. Exploratory biomarker analyses showed a decrease in plasma neurofilament light chain levels after treatment. Conclusions This early-phase study provides safety and tolerability data and exploratory efficacy findings for bosutinib in ALS. It also illustrates both the potential utility and limitations of external controls in a rare, rapidly progressive disease. Trial registration This trial was registered with ClinicalTrials.gov (NCT04744532) on February 9, 2021.
Authors
- Akiko Morinaga (ORCID: https://orcid.org/0009-0002-5357-6962)
- Takehisa Hirayama (ORCID: https://orcid.org/0000-0002-3056-3176)
- Motoki Oe
- Makiko Nagai (ORCID: https://orcid.org/0000-0001-6623-2187)
- Takao Kiriyama (ORCID: https://orcid.org/0000-0002-2282-0849)
- Takashi Ayaki (ORCID: https://orcid.org/0000-0003-0189-5910)
- Riko Tabuchi
- Ritsuko Hanajima
- Gen Sobue (ORCID: https://orcid.org/0000-0003-4769-5922)
- Takashi Nagasawa (ORCID: https://orcid.org/0000-0002-1600-1062)
- Yusuke Furukawa (ORCID: https://orcid.org/0000-0002-7249-6418)
- Kazuma Sugie (ORCID: https://orcid.org/0000-0003-0148-4687)
- Shotaro Haji (ORCID: https://orcid.org/0000-0003-4768-0317)
- Hitoki Nanaura (ORCID: https://orcid.org/0000-0002-0934-7065)
- Masahiro Nakamori (ORCID: https://orcid.org/0000-0002-0944-5538)
- Takenobu Murakami (ORCID: https://orcid.org/0000-0001-9042-5309)
- Naohiro Egawa (ORCID: https://orcid.org/0000-0001-9283-3170)
- Satoshi Morita (ORCID: https://orcid.org/0000-0002-4344-3317)
- Haruhisa Inoue (ORCID: https://orcid.org/0000-0003-4736-9537)
- Mihoko Kobayashi
- Codrin Lungu
- Kazutoshi Nishiyama
- Hiroshi Kataoka
- Koji Fujita
- Osamu Kano
- Hirofumi Maruyama
- Keiko Imamura
- Ryosuke Takahashi
- Naoki Atsuta
- Yuishin Izumi
- Kasia Lobello
- Yasuhiro Watanabe
Institutions
- Hiroshima University (JP)
- Toho University (JP)
- Aichi Medical University (JP)
- Pfizer (United States) (US)
- Akita University (JP)
- Kyoto University (JP)
- Kitasato University Hospital (JP)
- Pfizer (Japan) (JP)
- Center for iPS Cell Research and Application, Kyoto University (JP)
- Pfizer R&D Japan G.K. (Japan) (JP)
- Tottori University (JP)
- Kitasato University (JP)
- Nara Medical University (JP)
- Tokushima University (JP)
Publication Details
- Journal
- BMC Medicine
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1186/s12916-026-05410-w
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00